(redirected from Glycopeptide-Resistant Enterococci)
GREGraduate Record Examination
GREGender, Race and Ethnicity
GREGeneric Routing Encapsulation
GREGlass Reinforced Epoxy
GREGraduate Record Examinations
GREGradient Echo (magnetic resonance)
GREGoogle Result Element
GREGecko Runtime Environment
GREGraphics Rendering Engine
GREGraphics Engine
GREGlucocorticoid Response Element
GREGovernment Related Entity (various locations)
GREGraphics Rendering Engine (software)
GREGecko Runtime Environment (Mozilla browser)
GREGlycopeptide-Resistant Enterococci
GREGraduated Rate Estate (legal)
GREGuardian Royal Exchange (insurance)
GREGrass Roots Effort
GREGovernment Reporting Entity
GREGross Revenue Exclusion (Alaska oil production tax)
GREGeneral Research of Electronics, Inc
GREGraphite Epoxy
GREGroupe de Redéploiement Economique (Liège, Belgium)
GREGround Replay Equipment (aviation)
GREGround Runup Enclosure
GREGuest Relations Executive (hotel industry)
GREGetting Rid of Everything
GREGeneralized Ray Expansion (cavity analysis method)
GREGamma Ray Explorer
GREGTK+ Runtime Environment
GREGas Release Event
GREGreco Research Engineering Company, Inc.
GREGround Reconnaissance Equipment
GREGuardrail Enhancements
References in periodicals archive ?
Epidemiology of glycopeptide-resistant enterococci colonizing high risk patients in hospitals in Johannesburg, Republic of South Africa.
dagger]) Patient carrying an ESBL producer in addition to the carbapenemase-producing bacteria and/or glycopeptide-resistant enterococci.
From August 1998 to October 1999, glycopeptide-resistant enterococci (GRE) were isolated from 23 infected patients at a teaching hospital in Medellin, Colombia.
Since the initial discovery of glycopeptide-resistant enterococci (GRE) in the United Kingdom (18), nosocomial isolates of GRE have been reported from around the world (14); these isolates have also been found in healthy people in the community outside the hospital (19).
To the Editor: Glycopeptide-resistant enterococci infections are a major problem in hospitals.
To the Editor: Avilamycin and evernimicin (Ziracine), which belong to the everninomicin class of drugs, are oligosaccharide antibiotics active against numerous gram-positive bacteria, including emerging pathogens such as glycopeptide-resistant enterococci, methicillin-resistant staphylococci, and penicillin-resistant pneumococci (1,2).
Enterococci are ubiquitous in humans and animals and have a propensity for uptake and transfer of glycopeptide antibiotic resistance (3); therefore, the emergence of glycopeptide-resistant enterococci (ORE) in humans is a public health concern.
The increase in the incidence of glycopeptide-resistant enterococci (GRE) isolated from hospitalized patients throughout the United States has not been observed in France.
The incidence of enterobacteria producing extended-spectrum [Beta]-lactamases and glycopeptide-resistant enterococci remains rather low in France, as in most other European countries.